Tranexamic Acid Effective in Reducing Blood Loss in Revision Knee Surgery
Dallas, November 3, 2018 — A multicenter, randomized trial of patients undergoing revision total knee arthroplasty (TKA) sought to determine the optimal regimen of tranexamic acid to maximize its blood-sparing properties. The study, “A Multi-Center Randomized Clinical Trial of Tranexamic Acid in Revision Total Knee Arthroplasty: Does the Dosage Regimen Matter?,” was presented by Yale A. Fillingham, MD, at the 2018 American Association of Hip and Knee Surgeons Annual Meeting.
Dr. Fillingham and co-authors, Brian Darrith, MD, Tyler E. Calkins, BS, Matthew P. Abdel, MD, Arthur L. Malkani, MD, Ran Schwarzkopf, MD, Douglas E. Padgett, MD, Robert A. Sershon, MD, Stefano A. Bini, MD and Craig J. Della Valle, MD, conducted a randomized clinical trial where tranexamic acid was administered in different formulations (IV, topical, and/or oral) at different times. The results showed no significant difference in reduction in hemoglobin or calculated blood loss and transfusions.
The study concluded that all the tranexamic regimens tested had equivalent blood-sparing properties. The authors recommend that surgeons “consider using the lowest effective dose and the least costly regimen for TXA use in revision TKA.”
About the American Association of Hip and Knee Surgeons:
Established in 1991, the mission of AAHKS is to advance hip and knee patient care through education, advocacy and research. AAHKS has a membership of over 4,000 surgeons and other hip and knee health care professionals.
Denise Smith Rodd